Treatment of chronic hepatitis C in nonresponders to previous therapy

Todd E. Dantzler, Eric J. Lawitz

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


About 55% to 60% of treatment-naïve patients fail to achieve a sustained virologic response after therapy with standard interferon and ribavirin. The use of polyethylene glycol-enhanced interferon (PEG-IFN) plus ribavirin for retreatment of this challenging group is currently being evaluated by several investigators. Although no sustained virologic response rates have been reported yet from these trials, reported on-treatment response rates for previous nonresponders range from 25% to 30%, and an early estimate of the sustained virologic response rate is about 11%. Outcomes for treatment of relapsers and interferon monotherapy nonresponders have been significantly better than those for combination nonresponders. On-treatment responses of 40% to 43% in previous combination therapy nonresponders are now being seen with the addition of amantadine (triple therapy), and sustained response rates with this regimen are awaited. Large trials are underway to evaluate the role of maintenance therapy for virologic nonresponders with advanced liver disease.

Original languageEnglish (US)
Pages (from-to)78-85
Number of pages8
JournalCurrent Gastroenterology Reports
Issue number1
StatePublished - Feb 2003
Externally publishedYes

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Treatment of chronic hepatitis C in nonresponders to previous therapy'. Together they form a unique fingerprint.

Cite this